x) at CSL

Marburg, Hessen, Germany

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

PharmaceuticalsIndustries

Requirements

Kurz vor Abschluss des 2. Abschnitts der pharmazeutischen Ausbildung (2. Staatsexamen)
Motivation und Interesse für pharmazeutische Abläufe und Prozesse
Strukturierte Arbeitsweise
Teamfähigkeit und Offenheit für eine Zusammenarbeit mit Menschen verschiedener Kulturen
Gute Deutsch- und Englischkenntnisse in Wort und Schrift
Bewerbung mit üblichen Unterlagen, Aktueller Immatrikulationsbescheinigung, Nachweis für Pflichtpraktika (z.B. Auszug Praktikumsverordnung) und Arbeits- und Aufenthaltsgenehmigung (für nicht-europäische StudentInnen)

Responsibilities

Bearbeitung von pharmazeutisch-technischen Reklamationen
Mithilfe bei Inspektionen und Audits
Mitgestaltung des Praktikums nach eigenen Interessen
Einblick in gute Herstellpraxis von Arzneimitteln, Qualitätssicherungssysteme, Produktionsabläufe, Distribution, Arzneimittelsicherheit und andere Bereiche

Skills

GMP

Quality Management

Audits

Inspections

Pharmaceutical Complaints

Production Processes

Drug Safety

German

English

CSL

Develops biotherapies and influenza vaccines

About CSL

CSL develops and delivers biotherapies and influenza vaccines, focusing on rare and serious diseases. Their products include plasma-derived and recombinant therapies, which are created through extensive research and development. CSL serves a wide range of clients, including healthcare providers and governments, across the Americas, Asia Pacific, and Europe. What sets CSL apart from competitors is its comprehensive portfolio and commitment to addressing rare diseases, alongside a strong emphasis on diversity and inclusion within its workforce. The company's goal is to save lives and protect health through its innovative therapies and vaccines.

Parkville, AustraliaHeadquarters

1916Year Founded

$2,628.7MTotal Funding

ACQUISITIONCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Emerging synthetic biomaterials may reduce demand for traditional plasma therapies.

Jumar Bioincubator could increase local competition in the biotech sector.

CSL may need to adapt to the rising effectiveness of cell-based influenza vaccines.

Differentiation

CSL offers the broadest range of plasma-derived and recombinant therapies globally.

CSL's self-amplifying mRNA COVID-19 vaccine provides longer immunity at lower doses.

CSL's MF59® adjuvant enhances immune response, crucial for pandemic preparedness.

Upsides

CSL's garadacimab could be the first monthly treatment for hereditary angioedema.

CSL's cell-based influenza vaccine shows higher effectiveness over egg-based vaccines.

CSL's gene therapy HEMGENIX® offers a one-time treatment for haemophilia B.

Land your dream remote job 3x faster with AI

Try Jobo Free